These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37349676)

  • 1. PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation.
    Li X; Li X; Hu Y; Liu O; Wang Y; Li S; Yang Q; Lin B
    BMC Cancer; 2023 Jun; 23(1):573. PubMed ID: 37349676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
    Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
    J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Significance of Proteasome 26S Subunit, Non-ATPase (PSMD) Genes for Bladder Urothelial Carcinoma Patients.
    Salah Fararjeh A; Al-Khader A; Al-Saleem M; Abu Qauod R
    Cancer Inform; 2021; 20():11769351211067692. PubMed ID: 34992336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
    Li Y; Liu X; Zhao F; Zhao Z; Li X; Wang J; Huang B; Chen A
    CNS Neurosci Ther; 2024 Feb; 30(2):e14366. PubMed ID: 37485655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
    Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
    Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiles and prognostic values of BolA family members in ovarian cancer.
    Zhu M; Xiao S
    J Ovarian Res; 2021 Jun; 14(1):75. PubMed ID: 34078439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bioinformatics analysis of the clinicopathological and prognostic significance of
    Zheng HC; Ren DH; Zhang CY; Chen Y; Zhang L
    J Obstet Gynaecol; 2023 Dec; 43(1):2216280. PubMed ID: 37227120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian Cancer by Bioinformatics Analysis.
    Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
    Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients.
    Xuan DTM; Wu CC; Kao TJ; Ta HDK; Anuraga G; Andriani V; Athoillah M; Chiao CC; Wu YF; Lee KH; Wang CY; Chuang JY
    Aging (Albany NY); 2021 Nov; 13(22):24882-24913. PubMed ID: 34839279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
    Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
    Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular Analysis of Prognosis and Immune Infiltration of Ovarian Cancer Based on Homeobox D Genes.
    Chen B; Gao C; Wang H; Sun J; Han Z
    Comput Math Methods Med; 2022; 2022():3268386. PubMed ID: 36213580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
    Sun T; Bi F; Liu Z; Yang Q
    Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
    Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
    BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
    Han GH; Yun H; Chung JY; Kim JH; Cho H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma.
    Xu M; Jin T; Chen L; Zhang X; Zhu G; Wang Q; Lin Z
    Gene; 2019 May; 696():63-71. PubMed ID: 30776464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.